Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 315

The DOI matches its Crossref record; 80 of the 80 references it cites were found in a registry or an index.

Primary myelofibrosis: 2021 update on diagnosis, risk‐stratification and management

Open access
Tefferi, Ayalew·2021·American Journal of Hematology

Abstract

Disease Overview: Primary myelofibrosis (PMF) is a myeloproliferative neoplasm (MPN) characterized by stem cell‐derived clonal myeloproliferation that is often but not always accompanied by JAK2, CALR, or MPL mutations. Additional disease features include bone marrow reticulin/collagen fibrosis, aberrant inflammatory cytokine expression, anemia, hepatosplenomegaly, extramedullary hematopoiesis (EMH), constitutional symptoms, cachexia, leukemic progression, and shortened survival. Diagnosis: Bone marrow morphology is the primary basis for diagnosis. Presence of JAK2, CALR, or MPL mutation, expected in around 90% of the patients, is supportive but not essential for diagnosis; these mutations are also prevalent in the closely related MPNs, namely polycythemia vera (PV) and essential thrombocythemia (ET). The 2016 World Health Organization classification system distinguishes “prefibrotic” from “overtly fibrotic” PMF; the former might mimic ET in its presentation. Furthermore, approximately 15% of patients with ET or PV might progress into a PMF‐like phenotype (post‐ET/PV MF) during their clinical course. Adverse Mutations: SRSF2, ASXL1, and U2AF1‐Q157 mutations predict inferior survival in PMF, independent of each other and other risk factors. RAS/CBL mutations predicted resistance to ruxolitinib therapy. Adverse Karyotype: Very high risk abnormalities include −7, inv (3), i(17q), +21, +19, 12p‐, and 11q‐. Risk Stratification: Two new prognostic systems for PMF have recently been introduced: GIPSS (genetically‐inspired prognostic scoring system) and MIPSS70+ version 2.0 (MIPSS v2; mutation‐ and karyotype‐enhanced international prognostic scoring system). GIPSS is based exclusively on mutations and karyotype. MIPSS v2 includes, in addition, clinical risk factors. GIPSS features four and MIPSS v2 five risk categories. Risk‐adapted Therapy: Observation alone is advised for MIPSS v2 “low” and “very low” risk disease (estimated 10‐year survival 56%‐92%); allogeneic hematopoietic stem cell transplant (AHSCT) is the preferred treatment for “very high” and “high” risk disease (estimated 10‐year survival 0%‐13%); treatment‐requiring patients with intermediate‐risk disease (estimated 10‐year survival 30%) are best served by participating in clinical trials. In non‐transplant candidates, conventional treatment for anemia includes androgens, prednisone, thalidomide, and danazol; for symptomatic splenomegaly, hydroxyurea and ruxolitinib; and for constitutional symptoms, ruxolitinib. Fedratinib, another JAK2 inhibitor, has now been FDA‐approved for use in ruxolitinib failures. Splenectomy is considered for drug‐refractory splenomegaly and involved field radiotherapy for non‐hepatosplenic EMH and extremity bone pain. New Directions: A number of new agents, alone or in combination with ruxolitinib, are currently under investigation for MF treatment (ClinicalTrials.gov); preliminary results from some of these clinical trials were presented at the 2020 ASH annual meeting and highlighted in the current document.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/ajh.26050

Cites

80 of 80 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 80 references

Cited by

See all 315

Metadata

Authors
Tefferi, A.
Venue
American Journal of Hematology
Publisher
Wiley
Published
2020-12-02
Volume
96
Issue
1
Pages
145-162
ISSN
  • 0361-8609 (ISSN-L)
  • 1096-8652
OpenAlex
W3105658552
Cited by
315
References
80
FWCI
20.77
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Primary myelofibrosis: 2021 update on diagnosis, risk‐stratification and management. https://app.cochat.ai/papers/10.1002/ajh.26050
The paper
Tefferi, A. (2021). Primary myelofibrosis: 2021 update on diagnosis, risk‐stratification and management. American Journal of Hematology. https://doi.org/10.1002/ajh.26050

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.